From: Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Drug | Rationale | Developed by | Reference/Clinical Trial Identifier |
---|---|---|---|
CS-6253 | Increase APOE lipidation by activating ABCA1 | Tel Aviv University/Artery Therapeutics | Ref 125 |
CN-105 | APOE mimetic | CereNova/AegisCN LLC | Phase1: NCT02670824 (ICH); Ref 231 |
Phthalazinones, pyrazolines | Small molecule structure-correctors | Gladstone Institute/E-Scape bio | Ref 132 |
APOE antibody | Targeting non-lipidated APOE | Washington University/Denali therapeutics | Ref 99 |
Anti-sense oligonucleotide | Reduce expression of APOE4 | Washington University/Ionis | Ref 104 |
Gene Therapy | Biological: AAVrh.10 hAPOE2 vector | Cornell University | Phase 1: NCT03634007 |
Bexarotene | Alter APOE production, APOE lipidation and Aβ clearance | ReXceptor Inc. and C2N | Phase 1: NCT02061878 Outcome: No change in Aβ; increased CSF APOE |
Cleveland Clinic | Phase 2:NCT01782742 Outcome: No benefit in APOE4 patients; Ref 114 | ||
Probucol | Cholesterol lowering drug | McGill University/Douglas Hospital Research Center | Phase1/2: NCT02707458 Ref 232 |
AGB101 | Reduce APOE4-dependent abnormal hippocampal network activity | Medical College of Wisconsin | Phase 2: NCT03461861 Ref 233 |
Rosiglitazone | Anti-diabetic (APOE allele dependent response) | GlaxoSmithKline | Phase3: NCT00348140 Outcome:No effect on mild to moderate AD; Ref 234 |
Epigallocatechin gallate (EGCG) + multimodal intervention (diet, exercise) | Correct APOE4-dependent cognitive decline | Parc de Salut Mar | Recruiting: NCT03978052. No direct references found but see Ref 235 |
Exercise | Relationship of APOE4 to CBF and blood-based biomarkers (IGF-1, VEGF, BDNF) | University of Kansas Medical Center | Recruiting: NCT04009629 Ref 236 |